Comparison · NCT02678780-sae
Neuroendocrine Tumors of the Pancreas vs Neuroendocrine Tumors of Gastrointestinal Tract: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Neuroendocrine Tumors of the Pancreas vs Neuroendocrine Tumors of Gastrointestinal Tract: serious adverse events. Trial comparisons, record NCT02678780-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02678780-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.418 | 0.297 | 0.55 | wilson | |
| Risk in group 2 | 0.429 | 0.308 | 0.559 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0104 | -0.188 | 0.168 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.976 | 0.632 | 1.51 | log | |
| Odds ratio, group 1 over group 2 | 0.958 | 0.451 | 2.04 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Neuroendocrine Tumors of the Pancreas than on Neuroendocrine Tumors of Gastrointestinal Tract | 96.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Neuroendocrine Tumors of the Pancreas | Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.~Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)~Lenvatinib | 23 | 55 | EG000 |
| Group 2 | Neuroendocrine Tumors of Gastrointestinal Tract | Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)~Lenvatinib | 24 | 56 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 18 months
Source ClinicalTrials.gov
Trial
- Title
- Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
- NCT number
- NCT02678780
- Phases
- PHASE2
- Conditions
- Neuroendocrine Tumors
- Interventions
- Lenvatinib
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Results first posted
- 2025-07-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02678780?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02678780-sae